[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,746,164
  • Shares Outstanding, K 161,234
  • Annual Sales, $ 68,560 K
  • Annual Income, $ -437,990 K
  • EBIT $ -479 M
  • EBITDA $ -458 M
  • 60-Month Beta 1.66
  • Price/Sales 26.08
  • Price/Cash Flow N/A
  • Price/Book 2.02

Options Overview Details

View History
  • Implied Volatility 102.86% (+26.22%)
  • Historical Volatility 51.83%
  • IV Percentile 49%
  • IV Rank 11.00%
  • IV High 520.93% on 11/04/25
  • IV Low 51.19% on 07/31/25
  • Expected Move (DTE 23) 0.64 (5.97%)
  • Put/Call Vol Ratio 5.35
  • Today's Volume 324
  • Volume Avg (30-Day) 526
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 7,064
  • Open Int (30-Day) 12,981
  • Expected Range 10.03 to 11.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 6
  • High Estimate $0.79
  • Low Estimate $-0.86
  • Prior Year $-0.88
  • Growth Rate Est. (year over year) +98.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.26 +29.18%
on 03/30/26
11.66 -8.49%
on 04/20/26
+1.57 (+17.25%)
since 03/20/26
3-Month
6.86 +55.54%
on 02/05/26
11.66 -8.49%
on 04/20/26
+3.27 (+44.19%)
since 01/22/26
52-Week
4.16 +156.80%
on 08/11/25
11.66 -8.49%
on 04/20/26
+4.87 (+83.97%)
since 04/22/25

Most Recent Stories

More News
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500...

VIR : 10.67 (-1.48%)
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive...

VIR : 10.67 (-1.48%)
Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: ...

VIR : 10.67 (-1.48%)
Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 10.67 (-1.48%)
Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 10.67 (-1.48%)
Stock Index Futures Mixed With Focus on Trump’s SOTU Address and U.S. Economic Data

March S&P 500 E-Mini futures (ESH26) are down -0.04%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.21% this morning as sentiment remains cautious following yesterday’s selloff on Wall Street...

PYPL : 51.22 (+0.67%)
CEG : 287.16 (+3.41%)
JPM : 313.02 (+0.01%)
HIMS : 29.01 (-2.52%)
DDOG : 132.14 (+2.20%)
HPQ : 20.44 (-3.08%)
ESH26 : 6,594.63s (-0.22%)
WDAY : 126.60 (-1.98%)
IBM : 251.86 (-1.49%)
QCOM : 136.07 (+0.38%)
KDP : 26.54 (+0.38%)
KEYS : 338.97 (-0.10%)
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer ...

VIR : 10.67 (-1.48%)
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date ...

VIR : 10.67 (-1.48%)
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results...

VIR : 10.67 (-1.48%)
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta...

VIR : 10.67 (-1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 11.36
2nd Resistance Point 11.16
1st Resistance Point 10.91
Last Price 10.67
1st Support Level 10.47
2nd Support Level 10.27
3rd Support Level 10.03

See More

52-Week High 11.66
Last Price 10.67
Fibonacci 61.8% 8.79
Fibonacci 50% 7.91
Fibonacci 38.2% 7.02
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.